LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CDMO
      • Quality System
      • CDMO Service
      • Quality Control
      • Global CDMO
      • CDMO Inquiries
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • CDMO Inquiries
    • IR Inquiries
  • Stock Info
  • Disclosure
  • Financial Information
  • IR Inquiries

Disclosure

2023-09-22 14:19:13
No.DateDisclosure Contents
102023.09.18Ex-Rights(유상증자)
92023.09.18[Revised]Decision on Paid-in Capital Increase(주주배정후 실권주 일반공모)
82023.08.30[Revised]Decision on Paid-in Capital Increase(주주배정후 실권주 일반공모)
72023.08.16[Revised]Decision on Paid-in Capital Increase(주주배정후 실권주 일반공모)
62023.07.25Decision on Paid-in Capital Increase(주주배정후 실권주 일반공모)
52023.07.20Additional Listing(국내사모 CB전환)
42023.06.27Decision on Acquisition of Shares or Investment Securities of Other Corporation
32023.06.26Other Management Information(Voluntary Disclosure)(전환우선주 전환가액 조정)
22023.05.22[Revised]Decision on Acquisition of Shares or Investment Securities of Other Corporation
12023.05.22[Revised]Decision on Paid-in Capital Increase(Material Management Matters of Subsidiary Company)
  • Stock Info
  • Disclosure
  • Financial Information
  • IR Inquiries

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST